rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
6
|
pubmed:dateCreated |
1999-12-28
|
pubmed:abstractText |
Recombinant human bone morphogenetic protein-2 (rhBMP-2) was biotinated, and the bioactivity of biotinated protein was assessed in vitro (alkaline phosphate induction in limb bud cells) and in vivo (osteoinduction in the rat ectopic assay). Amino-biotinated rhBMP-2 exhibited an increase in bioactivity whereas carboxy-biotinated rhBMP-2 did not exhibit any changes in bioactivity in vitro. Avidin inhibited the bioactivity of amino-biotinated but not carboxyl-biotinated rhBMP-2. Both amino- and carboxy-modified rhBMP-2 induced bone at an equivalent level to that of unmodified rhBMP-2 in vivo. The presence of avidin did not affect the osteoinductive activity of both types of biotinated rhBMP-2. The overall results indicated that binding to a large protein, avidin, might affect rhBMP-2 activity in vitro depending on the binding site; however, in vivo activity was unaffected by the avidin binding.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Avidin,
http://linkedlifedata.com/resource/pubmed/chemical/BMP2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Bmp2 protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Morphogenetic Protein 2,
http://linkedlifedata.com/resource/pubmed/chemical/Bone Morphogenetic Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Implants,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/recombinant human bone...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0006-3592
|
pubmed:author |
|
pubmed:copyrightInfo |
Copyright 1999 John Wiley & Sons, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
65
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
668-72
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:10550773-Animals,
pubmed-meshheading:10550773-Avidin,
pubmed-meshheading:10550773-Binding Sites,
pubmed-meshheading:10550773-Biotinylation,
pubmed-meshheading:10550773-Bone Morphogenetic Protein 2,
pubmed-meshheading:10550773-Bone Morphogenetic Proteins,
pubmed-meshheading:10550773-Cell Line,
pubmed-meshheading:10550773-Dose-Response Relationship, Drug,
pubmed-meshheading:10550773-Drug Implants,
pubmed-meshheading:10550773-Humans,
pubmed-meshheading:10550773-Limb Buds,
pubmed-meshheading:10550773-Molecular Weight,
pubmed-meshheading:10550773-Osteogenesis,
pubmed-meshheading:10550773-Rats,
pubmed-meshheading:10550773-Rats, Long-Evans,
pubmed-meshheading:10550773-Recombinant Proteins,
pubmed-meshheading:10550773-Transforming Growth Factor beta
|
pubmed:year |
1999
|
pubmed:articleTitle |
Biotinated bone morphogenetic protein-2: In vivo and in vitro activity.
|
pubmed:affiliation |
Genetics Institute, Bone Biology and Application, One Burtt Road, Andover, Massachusetts 01810, USA. hasan.uludag@yakberta.ca
|
pubmed:publicationType |
Journal Article,
Comparative Study
|